Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of a 1-Piece Intraocular Lens

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Minimum 18 years of age~* Cataract for which phacoemulsification extraction and posterior chamber IOL implantation has been planned for both eyes~* Preoperative best corrected distance visual acuity (BCDVA)of 20/40 or worse (Snellen), with or without glare, for each eye~* BCDVA projected to be better than 20/30 following cataract removal and IOL implantation for each eye~* Preoperative keratometric cylinder of 0.75 diopters to 3.62 diopters for each eye (with exception of second eyes with 0.0-0.75 diopters planned to receive non-toric IOL)~* Clear intraocular media other than cataract in both eyes~* Availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures and study visits~* Signed informed consent and HIPAA authorization~Exclusion Criteria:~* Requiring IOLs outside spherical power range of +15.0 to +28.0 diopters~* Dilated pupil size less than 5.5 mm or the presence of any pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils)in either eye~* Previous corneal or intraocular surgery in either eye~* Irregular corneal astigmatism in either eye~* Corneal pathology/abnormality potentially affecting topography in either eye~* Corneal abnormalities such as stromal, epithelial or endothelial dystrophies in either eye~* Inability to achieve keratometric stability in either eye for contact lens wearers~* Subjects with diagnosed degenerative visual disorders in either eye(eg., macular degeneration or other retinal disorders) that are predicted to cause future acuity losses to a level of 20/30 or worse~* Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration, including pseudoexfoliation, trauma, or posterior capsule defects~* An eccentric anterior capsulorhexis, zonular damage/rupture or capsular tear/rupture during the cataract extraction procedure~* Use of systemic or ocular medications that may affect vision~* Prior, current, or anticipated use during the course of the nine month study of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo)likely to affect dilation or iris structure~* Poorly-controlled diabetes~* Acute, chronic, or uncontrolled systemic disease or illness that would, in the opinion of the investigator, increase the operative risk or confound the outcome(s) of the study (e.g., immunocompromised, connective tissue disease, etc.)~* Uncontrolled ocular hypertension or glaucomatous changes in the retina or visual field in either eye~* Known ocular disease or pathology that may affect visual acuity or that may require surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, etc.)~* Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes~* Concurrent participation or participation during 30 days prior to preoperative visit in any other clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control IOL (Type: ACTIVE_COMPARATOR): Approved Intraocular control lens
- Toric IOL (Type: EXPERIMENTAL): Investigational Toric IOL
- Higher Cylinder Toric IOL (Type: EXPERIMENTAL): Investigational Toric IOLs with higher cylinder powers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete